BioWorld - Tuesday, December 23, 2025
Breaking News: BioWorld Science 2025 Year in Review
See today's BioWorld Science
» Shanghai Xianxiang Medical Technology divulges new EGFR degradation inducers
Shanghai Xianxiang Medical Technology divulges new EGFR degradation inducers
Shanghai Xianxiang Medical Technology Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN)-binding moiety coupled to an EGFR (HER1; erbB1) mutant-targeting moiety through a linker reported to be useful for the treatment of cancer.
HIV research is close to a cure but far from ending the pandemic
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Researchers discover how glioblastoma tumors dodge chemotherapy
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...